Leerink Partners Raised Price Target on Globus Medical (GMED) Following Preliminary 4Q Results
Tweet Send to a Friend
Leerink Partners reiterated an Outperform rating on Globus Medical (NYSE: GMED), and raised the price target to $32.00 (from $31.00) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
